XIPERE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8636713 | BAUSCH AND LOMB INC | Methods and devices for drug delivery to ocular tissue using microneedle |
May, 2027
(3 years from now) | |
| US9636332 | BAUSCH AND LOMB INC | Methods and devices for the treatment of ocular diseases in human subjects |
Nov, 2033
(9 years from now) | |
| US9937075 | BAUSCH AND LOMB INC | Apparatus and methods for ocular injection |
May, 2034
(10 years from now) | |
Xipere is owned by Bausch And Lomb Inc.
Xipere contains Triamcinolone Acetonide.
Xipere has a total of 3 drug patents out of which 0 drug patents have expired.
Xipere was authorised for market use on 22 October, 2021.
Xipere is available in suspension;injection dosage forms.
Xipere can be used as treatment of macular edema associated with uveitis.
The generics of Xipere are possible to be released after 02 May, 2034.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 22, 2024 |
Drugs and Companies using TRIAMCINOLONE ACETONIDE ingredient
Market Authorisation Date: 22 October, 2021
Treatment: Treatment of macular edema associated with uveitis
Dosage: SUSPENSION;INJECTION
More Information on Dosage
XIPERE family patents
